Docetaxel （Beihai）

多西他赛（贝海生物）

Report date: 2026/05/12 20:00:17

Base Information

Drug NameDocetaxel （Beihai）
Drug Alias Name多西他赛注射液（不含吐温80型）BH009（多西他赛注射液（不含吐温80型））多西他赛注射液（白蛋白稳定型）BEIZRAYBH-009 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[10] 
Global Approved IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/10/23
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesZhuhai Beihai Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai Beihai Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A